Ischemic Hepatitis Treatment Market Report 2026

The ischemic hepatitis treatment market size has grown strongly in recent years. It will grow from $1.49 billion in 2025 to $1.63 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to rising incidence of cardiac failure and shock conditions, limited early diagnostic tools for liver ischemia, high mortality in untreated ischemic hepatitis cases, inadequate icu monitoring systems, growing prevalence of sepsis-related complications.

The ischemic hepatitis treatment market size is expected to see strong growth in the next few years. It will grow to $2.35 billion by 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to advancements in ai-based critical care decision support systems, increasing adoption of continuous hemodynamic monitoring technologies, growth in precision medicine for organ perfusion disorders, expansion of smart icu infrastructure globally, development of advanced hepatoprotective drug therapies. Major trends in the forecast period include ai-assisted liver perfusion monitoring systems in critical care, real-time hemodynamic instability detection using predictive analytics, cloud-based intensive care liver function tracking platforms, smart icu integration for organ perfusion optimization, remote patient monitoring systems for shock and sepsis management.

The increasing prevalence of cardiovascular diseases is anticipated to propel the growth of the ischemic hepatitis treatment market going forward. Cardiovascular diseases refer to a cluster of disorders impacting the heart and blood vessels, frequently resulting in reduced blood circulation and oxygen supply to vital organs. The prevalence of cardiovascular diseases is rising owing to aging populations, as advancing age contributes to a higher susceptibility to cardiac and vascular disorders. Ischemic hepatitis treatment supports cardiovascular diseases by stabilizing hepatic function and improving metabolic equilibrium in patients with impaired cardiac output, thereby helping to reduce complications arising from inadequate blood flow and enhancing overall clinical management of heart-related conditions. For instance, in June 2025, according to the UK Parliament's House of Commons Library, a UK-based government administration, during 2023-2024, England recorded 218,606 hospital admissions for coronary heart disease and 111,137 admissions for stroke. Therefore, the rising prevalence of cardiovascular diseases is contributing to the growth of the ischemic hepatitis treatment market.

The increasing burden of sepsis is expected to propel the growth of the ischemic hepatitis treatment market going forward. Sepsis is a life-threatening condition triggered by the body’s extreme response to infection, resulting in organ dysfunction and potential organ failure. The burden of sepsis is rising due to the increasing prevalence of severe infections, which escalate into systemic inflammatory responses affecting multiple organs. Ischemic hepatitis treatment supports sepsis management by stabilizing liver function, improving oxygen delivery, and preventing further hepatic injury, thereby helping to reduce systemic inflammation and enhancing overall organ recovery in patients experiencing severe infection-induced circulatory dysfunction. For instance, in March 2026, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, each year in the United States, at least 1.7 million adults and over 18,000 children develop sepsis, of whom more than 350,000 adults and 1,800 children either die during hospitalization or are discharged to hospice care. Therefore, the increasing burden of sepsis is contributing to the growth of the ischemic hepatitis treatment market.

The rising healthcare expenditure is expected to propel the growth of the ischemic hepatitis treatment market going forward. Healthcare expenditure refers to the total amount of resources spent on health services, including prevention, diagnosis, treatment, and management of diseases. Healthcare expenditure is increasing due to the rising prevalence of chronic and acute diseases, which require continuous treatment, advanced medical technologies, and long-term care services. Healthcare expenditure is contributing to ischemic hepatitis treatment by enabling increased investment in advanced diagnostic technologies, improving access to specialized medical care, and ensuring the availability of effective treatment options for managing liver-related complications. For instance, in January 2026, according to the Centers for Medicare & Medicaid Services, a US-based government agency, in 2024, national health expenditure (NHE) increased by 7.2% to $5.3 trillion, averaging $15,474 per person and representing 18% of GDP, while Medicare spending rose by 7.8% to $1.11 trillion, accounting for 21% of total NHE. Therefore, the rising healthcare expenditure is propelling the growth of the ischemic hepatitis treatment market.

Major companies operating in the ischemic hepatitis treatment market are Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, Linde plc, Medtronic plc, Koninklijke Philips N. V., GE HealthCare Technologies Inc., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Baxter International Inc., B. Braun SE, Fresenius Kabi AG, Grifols S. A., Terumo Corporation, Edwards Lifesciences Corporation, ResMed Inc., Drägerwerk AG & Co. KGaA, Getinge AB, ICU Medical Inc., Nihon Kohden Corporation, CAIRE Inc.

North America was the largest region in the ischemic hepatitis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic hepatitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ischemic hepatitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ischemic hepatitis treatment market consists of revenues earned by entities by providing services such as diagnostic evaluation, critical care monitoring, fluid and electrolyte management, and supportive therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The ischemic hepatitis treatment market also includes sales of cardiac drugs, antibiotics, and supportive therapeutic agents, liver function monitoring kits, and critical care equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.